FR16C0005I2 - Composes antiviraux - Google Patents

Composes antiviraux

Info

Publication number: FR16C0005I2
Authority: FR; France
Prior art keywords: antiviral compounds; antiviral; compounds
Prior art date: 2009-05-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR16C0005C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gilead Pharmasset LLC

Original Assignee

Gilead Pharmasset LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-13

Filing date

2016-02-05

Publication date

2016-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42645241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-02-05 Application filed by Gilead Pharmasset LLC filed Critical Gilead Pharmasset LLC

2016-03-25 Publication of FR16C0005I1 publication Critical patent/FR16C0005I1/fr

2016-09-30 Application granted granted Critical

2016-09-30 Publication of FR16C0005I2 publication Critical patent/FR16C0005I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

FR16C0005C 2009-05-13 2016-02-05 Composes antiviraux Active FR16C0005I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US17797209P	2009-05-13	2009-05-13
US22474509P	2009-07-10	2009-07-10
US23876009P	2009-09-01	2009-09-01
PCT/US2010/034600 WO2010132601A1 (fr)	2009-05-13	2010-05-12	Composés antiviraux

Publications (2)

Publication Number	Publication Date
FR16C0005I1 FR16C0005I1 (fr)	2016-03-25
FR16C0005I2 true FR16C0005I2 (fr)	2016-09-30

Family

ID=42645241

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR16C0005C Active FR16C0005I2 (fr)	2009-05-13	2016-02-05	Composes antiviraux

Country Status (40)

Country	Link
US (8)	US8088368B2 (fr)
EP (6)	EP2857394A1 (fr)
JP (7)	JP5582662B2 (fr)
KR (8)	KR20140122705A (fr)
CN (8)	CN104016971B (fr)
AP (2)	AP3622A (fr)
AR (1)	AR076765A1 (fr)
AU (1)	AU2010249043B2 (fr)
BR (3)	BRPI1010795B1 (fr)
CA (2)	CA2886322A1 (fr)
CL (1)	CL2011002825A1 (fr)
CO (1)	CO6470842A2 (fr)
CY (4)	CY1116942T1 (fr)
DK (3)	DK3002281T3 (fr)
EA (5)	EA026536B1 (fr)
EC (1)	ECSP11011517A (fr)
ES (4)	ES2646131T3 (fr)
FR (1)	FR16C0005I2 (fr)
HK (1)	HK1253517B (fr)
HR (3)	HRP20151000T8 (fr)
HU (4)	HUE030465T2 (fr)
IL (5)	IL216254A (fr)
LT (3)	LT3002281T (fr)
ME (3)	ME02536B (fr)
MX (6)	MX363732B (fr)
NL (1)	NL300796I2 (fr)
NO (3)	NO3002281T3 (fr)
NZ (3)	NZ706236A (fr)
PE (2)	PE20120509A1 (fr)
PL (4)	PL3002281T3 (fr)
PT (4)	PT2430014E (fr)
RS (3)	RS54386B8 (fr)
SG (2)	SG176015A1 (fr)
SI (4)	SI3309157T1 (fr)
SM (3)	SMT201700570T1 (fr)
TW (7)	TW201617073A (fr)
UA (1)	UA121454C2 (fr)
UY (1)	UY32629A (fr)
WO (1)	WO2010132601A1 (fr)
ZA (1)	ZA201108436B (fr)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4032897B1 (fr)	2003-05-30	2025-01-29	Gilead Pharmasset LLC	Analogues de nucléoside fluorés modifiés
BRPI0813999A2 (pt) *	2007-07-05	2019-10-01	Array Biopharma Inc	ciclopentanos de pirimidil como inibidores de akt proteína cinase
CN104163816A (zh)	2008-12-03	2014-11-26	普雷西迪奥制药公司	Hcv ns5a的抑制剂
WO2010065681A1 (fr) *	2008-12-03	2010-06-10	Presidio Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c de type ns5a
JP2012513410A (ja)	2008-12-23	2012-06-14	アボット・ラボラトリーズ	抗ウイルス化合物
MX2011006332A (es)	2008-12-23	2011-06-27	Abbott Lab	Compuestos antivirales.
US8314135B2 (en)	2009-02-09	2012-11-20	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole antivirals
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8637561B2 (en) *	2009-02-17	2014-01-28	Enanta Pharmaceuticals, Inc.	Linked diimidazole derivatives
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8188132B2 (en)	2009-02-17	2012-05-29	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US8242156B2 (en)	2009-02-17	2012-08-14	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
CA2753313A1 (fr) *	2009-02-23	2010-08-26	Presidio Pharmaceuticals, Inc.	Inhibiteurs du ns5a du vhc
US9765087B2 (en)	2009-02-27	2017-09-19	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8673954B2 (en)	2009-02-27	2014-03-18	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8101643B2 (en) *	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
CA2756255A1 (fr)	2009-03-27	2010-09-30	Presidio Pharmaceuticals, Inc.	Inhibiteurs bicycliques du vhc substitues
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en) *	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2419404B1 (fr)	2009-04-15	2015-11-04	AbbVie Inc.	Composes anti virale
CN102414199B (zh) *	2009-04-24	2014-03-05	泰博特克药品公司	二芳基醚
WO2010132538A1 (fr) *	2009-05-12	2010-11-18	Schering Corporation	Composés aryles tricycliques condensés utiles pour le traitement de maladies virales
MX363732B (es)	2009-05-13	2019-04-01	Gilead Pharmasset Llc Star	Compuestos antivirales.
US8138215B2 (en) *	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2435424B1 (fr) *	2009-05-29	2015-01-21	Merck Sharp & Dohme Corp.	Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
CA2762885A1 (fr) *	2009-05-29	2010-12-02	Schering Corporation	Composes antiviraux constitues de trois fractions d'aryle alignees pour traiter des maladies telles que l'hepatite c
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
DK2368890T3 (da) *	2009-06-11	2013-07-22	Abbvie Bahamas Ltd	Hepatitis C-virusinhibitorer
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US8609648B2 (en)	2009-07-02	2013-12-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
CN102656160A (zh)	2009-07-16	2012-09-05	顶点制药公司	用于治疗或预防黄病毒感染的苯并咪唑类似物
WO2011015658A1 (fr) *	2009-08-07	2011-02-10	Tibotec Pharmaceuticals	Dérivés de bis-benzimidazole en tant qu'inhibiteurs du virus de l'hépatite c
RU2538507C2 (ru) *	2009-08-07	2015-01-10	Тиботек Фармасьютикалз	Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
PE20120993A1 (es) *	2009-09-04	2012-08-22	Janssen Pharmaceuticals Inc	Derivados bifenilicos como antivirales
WO2011031934A1 (fr) *	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c
US9156818B2 (en) *	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8815928B2 (en) *	2009-09-11	2014-08-26	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8759332B2 (en) *	2009-09-11	2014-06-24	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8927709B2 (en) *	2009-09-11	2015-01-06	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8822700B2 (en)	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8703938B2 (en) *	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
UA108211C2 (uk) *	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110274648A1 (en) *	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en) *	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CN102482269B (zh) *	2009-12-04	2015-07-29	财团法人卫生研究院	脯氨酸衍生物
EP2512480A4 (fr) *	2009-12-14	2013-05-15	Enanta Pharm Inc	Inhibiteurs du virus de l'hépatite c
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011075607A1 (fr) *	2009-12-18	2011-06-23	Intermune, Inc.	Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
CA2784748A1 (fr) *	2009-12-18	2011-06-23	Idenix Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hepatite c a base de 5,5-arylene ou heteroarylene condense
US20130072523A1 (en) *	2009-12-24	2013-03-21	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
PE20130244A1 (es)	2010-01-25	2013-03-10	Enanta Pharm Inc	Inhibidores del virus de la hepatitis c
JP2013518062A (ja) *	2010-01-28	2013-05-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎阻害化合物
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
US8178531B2 (en) *	2010-02-23	2012-05-15	Enanta Pharmaceuticals, Inc.	Antiviral agents
WO2011109037A1 (fr) *	2010-03-04	2011-09-09	Enanta Pharmaceuticals, Inc.	Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la réplication du vhc
JP2013522375A (ja)	2010-03-24	2013-06-13	バーテックスファーマシューティカルズインコーポレイテッド	フラビウイルス感染を処置または予防するためのアナログ
EP2550268A1 (fr) *	2010-03-24	2013-01-30	Vertex Pharmaceuticals Incorporated	Analogues pour traiter ou prévenir les infections à flavivirus
WO2011127350A1 (fr)	2010-04-09	2011-10-13	Enanta Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c
US9125904B1 (en)	2010-05-11	2015-09-08	Achillion Pharmaceuticals, Inc.	Biphenyl imidazoles and related compounds useful for treating HCV infections
US20130296311A1 (en) *	2010-05-28	2013-11-07	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
EP2575819A4 (fr)	2010-06-04	2013-11-27	Enanta Pharm Inc	Inhibiteurs du virus de l'hépatite c
US20130310427A1 (en) *	2010-06-09	2013-11-21	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a protein
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
US8697704B2 (en)	2010-08-12	2014-04-15	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US20120195857A1 (en) *	2010-08-12	2012-08-02	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
AR082619A1 (es) *	2010-08-13	2012-12-19	Hoffmann La Roche	Inhibidores del virus de la hepatitis c
BR112013004520A2 (pt)	2010-08-26	2016-06-07	Univ Emory	inibidores potentes e seletivos do virus da hepatite c
WO2012050918A2 (fr)	2010-09-29	2012-04-19	Presidio Pharmaceutical, Inc.	Inhibiteurs de l'hépatite c tricyliques à cycles fusionnés
TWI548629B (zh) *	2010-11-17	2016-09-11	吉李德製藥公司	抗病毒化合物
RU2452735C1 (ru) *	2010-11-30	2012-06-10	Александр Васильевич Иващенко	Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20140364616A1 (en) *	2010-12-15	2014-12-11	Abbvie Inc.	Anti-viral compounds
WO2012083059A1 (fr) *	2010-12-15	2012-06-21	Abbott Laboratories	Composés anti-viraux
EP2651925A4 (fr) *	2010-12-15	2014-06-18	Abbvie Inc	Composés anti-viraux
CA2822037A1 (fr) *	2010-12-20	2012-06-28	Gilead Sciences, Inc.	Combinations pour traiter le vhc
WO2012087976A2 (fr) *	2010-12-21	2012-06-28	Intermune, Inc.	Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012188400A (ja) *	2011-03-11	2012-10-04	Tosoh Corp	ジチエノベンゾジチオフェンの製造方法
WO2012122716A1 (fr)	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Dérivés tétracycliques de xanthène et leurs procédés d'utilisation pour le traitement de maladies virales
US8835456B1 (en)	2011-03-18	2014-09-16	Achillion Pharmaceuticals, Inc.	NS5A inhibitors useful for treating HCV
US20120252721A1 (en) *	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) *	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
CN103687489A (zh)	2011-05-18	2014-03-26	埃南塔制药公司	制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
US8809313B2 (en)	2011-05-27	2014-08-19	Achillion Pharmaceuticals, Inc.	Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections
JP2014520822A (ja)	2011-07-09	2014-08-25	スンシネルアケプハルマカンパニーリミテッド	Ｃ型肝炎ウイルス阻害剤としてのスピロ化合物
PH12014500312A1 (en)	2011-08-08	2014-03-31	Lupin Ltd	Imidazole derivatives as antiviral agents
WO2013025975A1 (fr) *	2011-08-17	2013-02-21	Glaxosmithkline Llc	Traitements combinés pour l'hépatite c
CA2845321A1 (fr) *	2011-08-24	2013-02-28	Glaxosmithkline Llc	Traitements combines contre l'hepatite c
WO2013030750A1 (fr)	2011-09-01	2013-03-07	Lupin Limited	Composés antiviraux
CA2840242C (fr)	2011-09-16	2019-03-26	Gilead Sciences, Inc.	Procedes permettant de traiter le virus de l'hepatite c (hcv)
PT107894A (pt)	2011-10-21	2014-10-31	Abbvie Inc	Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
GB2515942A (en) *	2011-10-21	2015-01-07	Abbvie Inc	Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US9212168B2 (en)	2011-11-03	2015-12-15	Theravance Biopharma R&D Ip, Llc	Hepatitis C virus inhibitors
PL2635588T3 (pl) *	2011-11-16	2015-10-30	Gilead Pharmasset Llc	Skondensowane imidazoliloimidazole jako związki antywirusowe
WO2013098313A1 (fr)	2011-12-28	2013-07-04	Janssen R&D Ireland	Dérivés hétérobicycliques en tant qu'inhibiteurs de vhc
EP2907505A3 (fr) *	2011-12-29	2015-12-30	Abbvie Inc.	Compositions solides comprenant un inhibiteur du virus de l'hépatite C
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US9326973B2 (en) *	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2013217224B2 (en)	2012-02-10	2017-04-06	Lupin Limited	Antiviral compounds with a dibenzooxaheterocycle moiety
MD20140094A2 (ro)	2012-02-14	2015-03-31	University Of Georgia Research Foundation, Inc.	Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae
ITMI20120424A1 (it)	2012-03-19	2013-09-20	Rottapharm Spa	Composti chimici
CA2869908C (fr)	2012-04-25	2018-02-20	Theravance Biopharma R&D Ip, Llc	Inhibiteurs du virus de l'hepatite c
CA2869640C (fr)	2012-04-25	2018-03-20	Theravance Biopharma R&D Ip, Llc	Composes de piperazine-piperidine en tant qu'inhibiteurs du virus de l'hepatite c
US9079887B2 (en) *	2012-05-16	2015-07-14	Gilead Sciences, Inc.	Antiviral compounds
US20130309196A1 (en)	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
US9056860B2 (en)	2012-06-05	2015-06-16	Gilead Pharmasset Llc	Synthesis of antiviral compound
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
TWI610916B (zh)	2012-08-03	2018-01-11	廣東東陽光藥業有限公司	作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) *	2012-09-28	2014-04-01	Sunshine Lake Pharma Co Ltd	作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
TW201439084A (zh) *	2012-11-29	2014-10-16	Sunshine Lake Pharma Co Ltd	作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們在藥物中的應用
US9416139B2 (en)	2012-11-29	2016-08-16	Sunshine Lake Pharma Co., Ltd.	Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
CN103848818B (zh) *	2012-11-29	2017-03-15	广东东阳光药业有限公司	作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN103880823B (zh) *	2012-12-21	2017-12-05	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
KR20200060782A (ko)	2013-01-31	2020-06-01	길리애드 파마셋 엘엘씨	두 항바이러스 화합물의 병용 제형물
RU2518369C1 (ru) *	2013-02-07	2014-06-10	Общество с ограниченной ответственностью "Интеллектуальный Диалог"	Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
RU2507201C1 (ru) *	2013-02-07	2014-02-20	Александр Васильевич Иващенко	Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201439060A (zh) *	2013-02-27	2014-10-16	Sunshine Lake Pharma Co Ltd	作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20140357595A1 (en) *	2013-06-04	2014-12-04	Gilead Pharmasset Llc	Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
CN111116563B (zh) *	2013-06-06	2023-07-04	上海爱博医药科技有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2015009744A1 (fr)	2013-07-17	2015-01-22	Bristol-Myers Squibb Company	Associations comprenant des dérivés de biphényle destinées à être utilisées pour le traitement du virus de l'hépatite c
EP3650014B1 (fr)	2013-08-27	2021-10-06	Gilead Pharmasset LLC	Formulation de combinaison de deux composés antiviraux
CN104418785A (zh) *	2013-09-05	2015-03-18	浙江九洲药业股份有限公司	一种药物中间体的制备方法
WO2015042375A1 (fr)	2013-09-20	2015-03-26	Idenix Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c
CN104610272B (zh) *	2013-11-05	2017-03-29	上海唐润医药科技有限公司	环状黄酮或异黄酮类化合物及其用途
KR101561964B1 (ko)	2013-11-15	2015-10-20	한국과학기술연구원	옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
US20150150897A1 (en)	2013-12-02	2015-06-04	Gilead Pharmasset Llc	Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (zh)	2013-12-23	2016-03-16	吉李德製藥公司	固體型之抗病毒化合物
CN104725365B (zh) *	2013-12-23	2019-02-26	南京圣和药业股份有限公司	丙型肝炎病毒抑制剂及其应用
CA2935089C (fr) *	2013-12-31	2018-11-27	Nanjing Sanhome Pharmaceutical Co., Ltd.	Inhibiteur du virus de l'hepatite c a base de 9,9,10,10-tetrafluro-9,10-dihydrophenanthrene et son application
WO2015103490A1 (fr)	2014-01-03	2015-07-09	Abbvie, Inc.	Formes galéniques antivirales solides
CN104803989B (zh) *	2014-01-23	2017-12-22	广东东阳光药业有限公司	作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
CN107954997A (zh) *	2014-02-21	2018-04-24	常州寅盛药业有限公司	作为丙肝病毒抑制剂的联环化合物
CN104860931A (zh) *	2014-02-21	2015-08-26	常州寅盛药业有限公司	丙肝病毒抑制剂及其制药用途
WO2015184644A1 (fr) *	2014-06-06	2015-12-10	爱博新药研发(上海)有限公司	Composés et compositions pharmaceutiques destinés à inhiber le virus de l'hépatite c, et utilisations desdits composés et compositions
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
CN104140417B (zh) *	2014-06-11	2016-04-06	苏州景泓生物技术有限公司	合成gs5885用的中间体的先期化合物的合成方法
CN105524049B (zh) *	2014-09-28	2018-11-06	正大天晴药业集团股份有限公司	氘代的丙型肝炎病毒ns5a蛋白抑制剂
CN104513147B (zh) *	2014-11-20	2016-05-11	上海众强药业有限公司	芴乙酮衍生物的制备方法
TWI675029B (zh) *	2014-12-16	2019-10-21	大陸商廣東東陽光藥業有限公司	作為丙型肝炎抑制劑的橋環化合物及其製備方法
WO2016103232A1 (fr) *	2014-12-24	2016-06-30	Granules India Limited	Procédé amélioré de préparation d'inhibiteur du vhc
CN104530016A (zh) *	2014-12-25	2015-04-22	上海泓博智源医药技术有限公司	一种雷迪帕韦的制备方法及其中间体
SG11201705069YA (en)	2014-12-26	2017-07-28	Univ Emory	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP3256104A1 (fr)	2015-02-13	2017-12-20	Sandoz AG	Compositions pharmaceutiques à base de ledipasvir et de sofosbuvir
CN105985355B (zh) *	2015-03-01	2020-05-05	南京圣和药业股份有限公司	稠合三环类肝炎病毒抑制剂及其应用
AU2016216673B2 (en)	2015-03-04	2017-02-02	Gilead Sciences, Inc.	Toll like receptor modulator compounds
WO2016145269A1 (fr)	2015-03-12	2016-09-15	Teva Pharmaceuticals International Gmbh	Formes solides de lédipasvir et procédés pour la préparation de lédipasvir
CN104829599B (zh) *	2015-03-17	2017-06-09	上海众强药业有限公司	雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
CN105017228A (zh) *	2015-07-03	2015-11-04	上海众强药业有限公司	一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法
PE20180928A1 (es)	2015-07-24	2018-06-08	Newlink Genetics Corp	Sales y profarmacos de 1-metil-d-triptofano
US10617675B2 (en)	2015-08-06	2020-04-14	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR101919194B1 (ko) *	2015-09-15	2018-11-15	주식회사 엘지화학	헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105294713A (zh) *	2015-10-09	2016-02-03	重庆康施恩化工有限公司	Velpatasvir中间体及其制备方法
WO2017072596A1 (fr)	2015-10-26	2017-05-04	Optimus Drugs (P) Ltd	Procédé amélioré pour la préparation de lédipasvir
WO2017072714A1 (fr)	2015-10-30	2017-05-04	Lupin Limited	Prémélange de ledipasvir stable et son procédé de préparation
WO2017076201A1 (fr) *	2015-11-06	2017-05-11	江苏豪森药业集团有限公司	Inhibiteurs du vhc, leur procédé de préparation et leur utilisation
CN106117187B (zh) *	2016-01-12	2019-01-01	深圳市塔吉瑞生物医药有限公司	一种丙型肝炎病毒抑制剂、药物组合物及其应用
EP3411369A1 (fr) *	2016-02-01	2018-12-12	Lupin Limited	Procédé de préparation de lédipasvir et d'intermédiaires de ce dernier
WO2017145028A1 (fr) *	2016-02-26	2017-08-31	Glenmark Pharmaceuticals Limited	Procédé de préparation de lédipasvir
WO2017184670A2 (fr)	2016-04-22	2017-10-26	Gilead Sciences, Inc.	Méthodes de traitement d'infections à virus zika
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP4491236A3 (fr)	2016-05-10	2025-04-02	C4 Therapeutics, Inc.	Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197036A1 (fr)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
EP3455219A4 (fr)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
WO2017195147A1 (fr)	2016-05-12	2017-11-16	Lupin Limited	Procédé de préparation de lédipasvir et d'intermédiaires de ce dernier
EP3463469B1 (fr)	2016-05-27	2023-12-13	Gilead Sciences, Inc.	Combinaision de ledipasvir et sofosbuvir pour l'utilisation dans le traitement de l'hepatite b chez l'homme
BR102017011025A2 (pt)	2016-06-02	2017-12-19	Gilead Pharmasset Llc	Formulation of combination of three antiviral compounds
CN107663196A (zh) *	2016-07-27	2018-02-06	广东东阳光药业有限公司	制备化合物的方法
WO2018035410A1 (fr) *	2016-08-19	2018-02-22	Temple University-Of The Commonwealth System Of Higher Education	Compositions et procédés de traitement utilisant des analogues d'adn de taille étendue
AU2017318601B2 (en)	2016-09-02	2020-09-03	Gilead Sciences, Inc.	Toll like receptor modulator compounds
US10640499B2 (en)	2016-09-02	2020-05-05	Gilead Sciences, Inc.	Toll like receptor modulator compounds
JP2018095561A (ja) *	2016-12-08	2018-06-21	金剛化学株式会社	ジフェニルアゼチジン誘導体の製造方法
CN106632275B (zh) *	2016-12-20	2018-03-06	上海同昌生物医药科技有限公司	一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体
RU2650610C1 (ru)	2017-02-28	2018-04-16	Васильевич Иващенко Александр	Противовирусная композиция и способ ее применения
US10392370B2 (en)	2017-03-13	2019-08-27	Optimus Drugs Pvt Ltd	Process for the preparation of Daclatasvir dihydrochloride and its intermediates
JOP20180040A1 (ar)	2017-04-20	2019-01-30	Gilead Sciences Inc	مثبطات pd-1/pd-l1
CA3063288A1 (fr)	2017-05-12	2018-11-15	Mavalon Therapeutics Limited	Composes heterocycliques substitues utilises comme modulateurs allosteriques de recepteurs metabotropiques du glutamate du groupe ii
CN118440096A (zh)	2017-06-20	2024-08-06	C4医药公司	用于蛋白降解的n/o-连接的降解决定子和降解决定子体
PL3706762T3 (pl)	2017-12-07	2025-02-10	Emory University	N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
JP7062792B2 (ja)	2018-02-13	2022-05-06	ギリアードサイエンシーズ，インコーポレイテッド	Ｐｄ－１／ｐｄ－ｌ１阻害剤
EP3781556B1 (fr)	2018-04-19	2025-06-18	Gilead Sciences, Inc.	Inhibiteurs pd-1/pd-l1
WO2019222146A1 (fr)	2018-05-15	2019-11-21	University Of Louisville Research Foundation, Inc.	Urolithine a et ses dérivés destinés à être utilisés en thérapie
CN118221646A (zh)	2018-07-13	2024-06-21	吉利德科学公司	Pd-1/pd-l1抑制剂
KR102635333B1 (ko)	2018-10-24	2024-02-15	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
WO2020219808A1 (fr) *	2019-04-25	2020-10-29	Beta Pharma, Inc.	Inhibiteurs dicarbamate de ns5a pour le traitement d'infections par le virus de l'hépatite c et de maladies associées
CA3140708A1 (fr)	2019-06-18	2020-12-24	Helen Horton	Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de pyridopyrimidine
CA3169676A1 (fr) *	2020-02-28	2021-09-02	Dominic Reynolds	Composes et procedes de modulation de l'epissage
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4079748A1 (fr)	2021-04-23	2022-10-26	Insusense ApS	Modulateurs de la activité de sortiline
EP4089102A1 (fr)	2021-05-14	2022-11-16	Insusense ApS	Modulateurs de la activité de sortiline
CA3220903A1 (fr)	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Derives pentacycliques en tant qu'inhibiteurs du virus zika
CA3219397A1 (fr) *	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Composes tetracycliques pour le traitement d'une infection par le virus zika
WO2023283256A1 (fr)	2021-07-09	2023-01-12	Aligos Therapeutics, Inc.	Composés anti-viraux
WO2023043816A1 (fr) *	2021-09-17	2023-03-23	Aligos Therapeutics, Inc.	Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus
CN118660876A (zh) *	2022-02-11	2024-09-17	波涛生命科学有限公司	手性化合物的立体选择性技术
CN117567414A (zh) *	2023-10-13	2024-02-20	濮阳惠成电子材料股份有限公司	一种光电材料中间体1-溴二苯并呋喃的合成方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
DE69115694T2 (de)	1990-06-13	1996-10-17	Arnold Newton Mass. Glazier	Phosphorylierte prodrugs
DE10399025I2 (de)	1990-09-14	2007-11-08	Acad Of Science Czech Republic	Wirkstoffvorläufer von Phosphonaten
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
EP2316839B1 (fr)	2004-07-16	2014-03-12	Gilead Sciences, Inc.	Composés hétérocycliques antiviraux avec des groupes phosphonates
US7323447B2 (en) *	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8143288B2 (en) *	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7659270B2 (en) *	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8303944B2 (en) *	2006-08-11	2012-11-06	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7759495B2 (en)	2006-08-11	2010-07-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US7741347B2 (en)	2007-05-17	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20100160335A1 (en) *	2007-06-19	2010-06-24	Kyorin Pharmaceutical Co., Ltd.	Pyridazinone derivative and pde inhibitor containing the same as active ingredient
US7728027B2 (en)	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) *	2007-08-08	2014-01-14	Bristol-Myers Squibb Company	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
NZ587323A (en)	2008-02-12	2012-02-24	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US8147818B2 (en) *	2008-02-13	2012-04-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7704992B2 (en) *	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP5312486B2 (ja)	2008-02-13	2013-10-09	ブリストル−マイヤーズスクイブカンパニー	Ｃ型肝炎ウイルス阻害剤
GB2457659A (en)	2008-02-19	2009-08-26	Malcolm Mulheron	Foldable meal tray
WO2010004843A1 (fr)	2008-07-08	2010-01-14	Ntn株式会社	Dispositif de réduction
CN102083813A (zh)	2008-07-10	2011-06-01	普洛希典有限公司	哌啶基gpcr激动剂
US7906655B2 (en) *	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8383094B2 (en) *	2008-10-01	2013-02-26	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010062821A1 (fr)	2008-11-28	2010-06-03	Glaxosmithkline Llc	Composés antiviraux, compositions, et procédés d’utilisation
WO2010065681A1 (fr) *	2008-12-03	2010-06-10	Presidio Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c de type ns5a
CN104163816A (zh) *	2008-12-03	2014-11-26	普雷西迪奥制药公司	Hcv ns5a的抑制剂
EP2393359A4 (fr)	2009-02-09	2012-10-03	Enanta Pharm Inc	Dérivés du dibenzimidazole liés
WO2010096462A1 (fr)	2009-02-17	2010-08-26	Enanta Pharmaceuticals, Inc	Dérivés du diimidazole lié
TWI438200B (zh)	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
WO2010094977A1 (fr)	2009-02-23	2010-08-26	Arrow Therapeutics Limited	Nouveaux composés de biphényle utiles pour le traitement de l'hépatite c
CA2753313A1 (fr)	2009-02-23	2010-08-26	Presidio Pharmaceuticals, Inc.	Inhibiteurs du ns5a du vhc
KR20130130875A (ko)	2009-02-27	2013-12-02	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
EP2623104A1 (fr)	2009-03-20	2013-08-07	Alios Biopharma, Inc.	Analogues nucléosidiques et nucléotidiques substitués
KR20110131312A (ko)	2009-03-27	2011-12-06	프레시디오 파마슈티칼스, 인코포레이티드	융합된 고리 ｃ형 간염 억제제
JP5913091B2 (ja)	2009-03-27	2016-04-27	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃ型肝炎ウイルス複製の阻害剤
CA2756255A1 (fr)	2009-03-27	2010-09-30	Presidio Pharmaceuticals, Inc.	Inhibiteurs bicycliques du vhc substitues
TWI476190B (zh) *	2009-03-30	2015-03-11	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8796466B2 (en) *	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en)	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2419404B1 (fr)	2009-04-15	2015-11-04	AbbVie Inc.	Composes anti virale
CN102414199B (zh)	2009-04-24	2014-03-05	泰博特克药品公司	二芳基醚
WO2010132538A1 (fr) *	2009-05-12	2010-11-18	Schering Corporation	Composés aryles tricycliques condensés utiles pour le traitement de maladies virales
MX363732B (es) *	2009-05-13	2019-04-01	Gilead Pharmasset Llc Star	Compuestos antivirales.
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2762885A1 (fr)	2009-05-29	2010-12-02	Schering Corporation	Composes antiviraux constitues de trois fractions d'aryle alignees pour traiter des maladies telles que l'hepatite c
EP2435424B1 (fr)	2009-05-29	2015-01-21	Merck Sharp & Dohme Corp.	Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
DK2368890T3 (da) *	2009-06-11	2013-07-22	Abbvie Bahamas Ltd	Hepatitis C-virusinhibitorer
US8221737B2 (en) *	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2010148006A1 (fr)	2009-06-16	2010-12-23	Enanta Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c
WO2011004276A1 (fr)	2009-07-06	2011-01-13	Pfizer Limited	Inhibiteurs du virus de lhépatite c
CN102656160A (zh)	2009-07-16	2012-09-05	顶点制药公司	用于治疗或预防黄病毒感染的苯并咪唑类似物
RU2538507C2 (ru)	2009-08-07	2015-01-10	Тиботек Фармасьютикалз	Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
WO2011015658A1 (fr)	2009-08-07	2011-02-10	Tibotec Pharmaceuticals	Dérivés de bis-benzimidazole en tant qu'inhibiteurs du virus de l'hépatite c
FR2949465B1 (fr)	2009-09-01	2011-08-12	Pf Medicament	Derives chromones, leur procede de preparation et leurs applications therapeutiques
CA2772484A1 (fr)	2009-09-03	2011-03-10	Tibotec Pharmaceuticals	Derives de bis-benzimidazole
PE20120993A1 (es)	2009-09-04	2012-08-22	Janssen Pharmaceuticals Inc	Derivados bifenilicos como antivirales
WO2011031934A1 (fr)	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c
US9156818B2 (en)	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8415374B2 (en)	2009-10-12	2013-04-09	Bristol-Myers Squibb Company	Combinations of hepatitis C virus inhibitors
WO2011050146A1 (fr)	2009-10-23	2011-04-28	Glaxosmithkline Llc	Composés chimiques
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CA2782024A1 (fr)	2009-11-25	2011-06-03	Schering Corporation	Composes tricycliques fusionnes et leurs derives utiles pour le traitement de maladies virales
US20110137633A1 (en) *	2009-12-03	2011-06-09	Abbott Laboratories	Anti-viral compounds and methods of identifying the same
EP2512480A4 (fr) *	2009-12-14	2013-05-15	Enanta Pharm Inc	Inhibiteurs du virus de l'hépatite c
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011075607A1 (fr)	2009-12-18	2011-06-23	Intermune, Inc.	Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
CA2784748A1 (fr) *	2009-12-18	2011-06-23	Idenix Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hepatite c a base de 5,5-arylene ou heteroarylene condense
WO2011087740A1 (fr)	2009-12-22	2011-07-21	Schering Corporation	Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
US20130072523A1 (en)	2009-12-24	2013-03-21	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011091446A1 (fr)	2010-01-22	2011-07-28	Glaxosmithkline Llc	Composés chimiques
CN102918049A (zh)	2010-03-09	2013-02-06	默沙东公司	稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
WO2011146401A1 (fr)	2010-05-17	2011-11-24	Intermune, Inc.	Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
US8815858B2 (en) *	2010-05-21	2014-08-26	Gilead Sciences, Inc.	Heterocyclic flaviviridae virus inhibitors
TW201211047A (en) *	2010-06-10	2012-03-16	Gilead Sciences Inc	Methods for treating HCV
BR112013004520A2 (pt)	2010-08-26	2016-06-07	Univ Emory	inibidores potentes e seletivos do virus da hepatite c
AU2011307953B2 (en)	2010-09-29	2014-07-31	Merck Sharp & Dohme Corp.	Tetracyclic indole derivatives for treating hepatitis C virus infection
WO2012048421A1 (fr)	2010-10-14	2012-04-19	Boehringer Ingelheim International Gmbh	Composés inhibiteurs de l'hépatite c
TWI548629B (zh)	2010-11-17	2016-09-11	吉李德製藥公司	抗病毒化合物
CA2822037A1 (fr)	2010-12-20	2012-06-28	Gilead Sciences, Inc.	Combinations pour traiter le vhc
WO2012087976A2 (fr)	2010-12-21	2012-06-28	Intermune, Inc.	Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
CA2840242C (fr) *	2011-09-16	2019-03-26	Gilead Sciences, Inc.	Procedes permettant de traiter le virus de l'hepatite c (hcv)
PL2635588T3 (pl)	2011-11-16	2015-10-30	Gilead Pharmasset Llc	Skondensowane imidazoliloimidazole jako związki antywirusowe
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
US8841340B2 (en) *	2012-08-17	2014-09-23	Gilead Sciences, Inc.	Solid forms of an antiviral compound

2010
- 2010-05-12 MX MX2014006862A patent/MX363732B/es unknown
- 2010-05-12 LT LTEP15180635.3T patent/LT3002281T/lt unknown
- 2010-05-12 RS RS20150758A patent/RS54386B8/sr unknown
- 2010-05-12 TW TW104133224A patent/TW201617073A/zh unknown
- 2010-05-12 RS RS20160824A patent/RS55249B8/sr unknown
- 2010-05-12 EA EA201490854A patent/EA026536B1/ru unknown
- 2010-05-12 TW TW099115093A patent/TWI465444B/zh active
- 2010-05-12 CN CN201410227599.2A patent/CN104016971B/zh active Active
- 2010-05-12 EP EP20140175570 patent/EP2857394A1/fr not_active Withdrawn
- 2010-05-12 EP EP14175539.7A patent/EP2873665B1/fr active Active
- 2010-05-12 JP JP2012510987A patent/JP5582662B2/ja active Active
- 2010-05-12 BR BRPI1010795A patent/BRPI1010795B1/pt active IP Right Grant
- 2010-05-12 PL PL15180635T patent/PL3002281T3/pl unknown
- 2010-05-12 TW TW109105841A patent/TW202042807A/zh unknown
- 2010-05-12 PE PE2011001965A patent/PE20120509A1/es active IP Right Grant
- 2010-05-12 BR BR122014013631A patent/BR122014013631B8/pt active IP Right Grant
- 2010-05-12 AP AP2011005987A patent/AP3622A/xx active
- 2010-05-12 WO PCT/US2010/034600 patent/WO2010132601A1/fr not_active Ceased
- 2010-05-12 EA EA201790515A patent/EA037281B1/ru unknown
- 2010-05-12 CN CN201811070551.XA patent/CN109020961A/zh active Pending
- 2010-05-12 ES ES15180635.3T patent/ES2646131T3/es active Active
- 2010-05-12 TW TW105117036A patent/TWI629981B/zh active
- 2010-05-12 TW TW107113373A patent/TWI689305B/zh active
- 2010-05-12 KR KR1020147016501A patent/KR20140122705A/ko not_active Ceased
- 2010-05-12 PL PL14175539T patent/PL2873665T3/pl unknown
- 2010-05-12 CN CN201410226959.7A patent/CN104211689B/zh active Active
- 2010-05-12 MX MX2011012058A patent/MX2011012058A/es active IP Right Grant
- 2010-05-12 KR KR1020187006008A patent/KR20180028070A/ko not_active Ceased
- 2010-05-12 EA EA201490853A patent/EA201490853A1/ru unknown
- 2010-05-12 CN CN201080029503.1A patent/CN102596936B/zh active Active
- 2010-05-12 EA EA201590073A patent/EA027493B1/ru unknown
- 2010-05-12 NZ NZ706236A patent/NZ706236A/en unknown
- 2010-05-12 CN CN201410226767.6A patent/CN104230900B/zh active Active
- 2010-05-12 MX MX2014005805A patent/MX360803B/es unknown
- 2010-05-12 CN CN201611104976.9A patent/CN106588890B/zh active Active
- 2010-05-12 BR BR122014012810A patent/BR122014012810B1/pt active IP Right Grant
- 2010-05-12 HU HUE14175539A patent/HUE030465T2/hu unknown
- 2010-05-12 PT PT107209702T patent/PT2430014E/pt unknown
- 2010-05-12 CN CN201410227574.2A patent/CN104211713B/zh active Active
- 2010-05-12 ME MEP-2016-215A patent/ME02536B/fr unknown
- 2010-05-12 PL PL10720970T patent/PL2430014T3/pl unknown
- 2010-05-12 HU HUE15180635A patent/HUE036906T2/hu unknown
- 2010-05-12 KR KR1020117029699A patent/KR101546119B1/ko active Active
- 2010-05-12 KR KR1020167017466A patent/KR101727876B1/ko active Active
- 2010-05-12 HR HRP20151000TT patent/HRP20151000T8/hr unknown
- 2010-05-12 DK DK15180635.3T patent/DK3002281T3/en active
- 2010-05-12 NZ NZ61920510A patent/NZ619205A/en unknown
- 2010-05-12 SI SI201031950T patent/SI3309157T1/sl unknown
- 2010-05-12 LT LTEP14175539.7T patent/LT2873665T/lt unknown
- 2010-05-12 NZ NZ596444A patent/NZ596444A/en unknown
- 2010-05-12 AP AP2016008993A patent/AP2016008993A0/xx unknown
- 2010-05-12 ES ES17190692T patent/ES2758726T3/es active Active
- 2010-05-12 RS RS20171281A patent/RS56654B8/sr unknown
- 2010-05-12 DK DK14175539.7T patent/DK2873665T3/en active
- 2010-05-12 MX MX2019003738A patent/MX376550B/es active IP Right Grant
- 2010-05-12 KR KR1020207001908A patent/KR20200011049A/ko not_active Ceased
- 2010-05-12 SI SI201031024T patent/SI2430014T1/sl unknown
- 2010-05-12 PT PT171906928T patent/PT3309157T/pt unknown
- 2010-05-12 CN CN201410226164.6A patent/CN103977406B/zh active Active
- 2010-05-12 AU AU2010249043A patent/AU2010249043B2/en active Active
- 2010-05-12 CA CA2886322A patent/CA2886322A1/fr not_active Abandoned
- 2010-05-12 DK DK10720970.2T patent/DK2430014T3/en active
- 2010-05-12 SM SM20170570T patent/SMT201700570T1/it unknown
- 2010-05-12 ME MEP-2015-196A patent/ME02321B/me unknown
- 2010-05-12 SI SI201031554T patent/SI3002281T1/sl unknown
- 2010-05-12 TW TW103134405A patent/TW201503888A/zh unknown
- 2010-05-12 KR KR1020147016504A patent/KR101503752B1/ko active Active
- 2010-05-12 MX MX2014005933A patent/MX360800B/es unknown
- 2010-05-12 CA CA2761258A patent/CA2761258C/fr active Active
- 2010-05-12 TW TW103134406A patent/TWI547495B/zh active
- 2010-05-12 US US12/779,023 patent/US8088368B2/en active Active
- 2010-05-12 ES ES10720970.2T patent/ES2548156T3/es active Active
- 2010-05-12 KR KR1020177009423A patent/KR20170041924A/ko not_active Ceased
- 2010-05-12 UA UAA201413049A patent/UA121454C2/uk unknown
- 2010-05-12 SI SI201031290T patent/SI2873665T1/sl unknown
- 2010-05-12 UY UY0001032629A patent/UY32629A/es not_active Application Discontinuation
- 2010-05-12 PT PT151806353T patent/PT3002281T/pt unknown
- 2010-05-12 AR ARP100101639A patent/AR076765A1/es not_active Application Discontinuation
- 2010-05-12 NO NO15180635A patent/NO3002281T3/no unknown
- 2010-05-12 EP EP19193481.9A patent/EP3626716A1/fr not_active Withdrawn
- 2010-05-12 KR KR1020197007083A patent/KR20190029771A/ko not_active Ceased
- 2010-05-12 ES ES14175539.7T patent/ES2596247T3/es active Active
- 2010-05-12 ME MEP-2017-262A patent/ME02916B/fr unknown
- 2010-05-12 HU HUE10720970A patent/HUE025983T2/en unknown
- 2010-05-12 PL PL17190692T patent/PL3309157T3/pl unknown
- 2010-05-12 EA EA201190259A patent/EA021974B1/ru active Protection Beyond IP Right Term
- 2010-05-12 SG SG2011083151A patent/SG176015A1/en unknown
- 2010-05-12 PT PT141755397T patent/PT2873665T/pt unknown
- 2010-05-12 EP EP10720970.2A patent/EP2430014B1/fr active Active
- 2010-05-12 EP EP15180635.3A patent/EP3002281B1/fr active Active
- 2010-05-12 EP EP17190692.8A patent/EP3309157B1/fr active Active
- 2010-05-12 SG SG10201402280QA patent/SG10201402280QA/en unknown
- 2010-05-12 PE PE2014001982A patent/PE20150202A1/es active IP Right Grant
2011
- 2011-11-08 US US13/291,977 patent/US8273341B2/en active Active
- 2011-11-10 IL IL216254A patent/IL216254A/en active IP Right Grant
- 2011-11-11 MX MX2020011251A patent/MX2020011251A/es unknown
- 2011-11-11 CL CL2011002825A patent/CL2011002825A1/es unknown
- 2011-11-17 ZA ZA2011/08436A patent/ZA201108436B/en unknown
- 2011-11-30 CO CO11164618A patent/CO6470842A2/es active IP Right Grant
- 2011-12-12 EC EC2011011517A patent/ECSP11011517A/es unknown
2012
- 2012-06-07 US US13/491,446 patent/US8669234B2/en active Active
- 2012-07-19 US US13/553,517 patent/US8575118B2/en active Active
2013
- 2013-07-31 US US13/956,195 patent/US8822430B2/en active Active
- 2013-10-03 US US14/045,717 patent/US8841278B2/en active Active
2014
- 2014-05-16 US US14/280,478 patent/US9511056B2/en active Active
- 2014-05-23 JP JP2014107359A patent/JP5744283B2/ja active Active
- 2014-06-10 IL IL233044A patent/IL233044A/en active IP Right Grant
- 2014-06-10 IL IL233042A patent/IL233042A0/en unknown
- 2014-06-17 JP JP2014124325A patent/JP5745727B2/ja active Active
- 2014-07-17 IL IL233678A patent/IL233678B/en active IP Right Grant
- 2014-07-17 IL IL233679A patent/IL233679B/en active IP Right Grant
2015
- 2015-04-28 JP JP2015091474A patent/JP2015157842A/ja not_active Withdrawn
- 2015-11-17 CY CY20151101032T patent/CY1116942T1/el unknown
- 2015-11-19 SM SM201500284T patent/SMT201500284B/it unknown
2016
- 2016-01-07 HU HUS1600001C patent/HUS1600001I1/hu unknown
- 2016-01-11 LT LTPA2016002C patent/LTC2430014I2/lt unknown
- 2016-01-22 CY CY2016001C patent/CY2016001I1/el unknown
- 2016-02-05 FR FR16C0005C patent/FR16C0005I2/fr active Active
- 2016-02-17 NO NO2016004C patent/NO2016004I2/no not_active IP Right Cessation
- 2016-02-18 NL NL300796C patent/NL300796I2/nl unknown
- 2016-09-28 US US15/279,303 patent/US9981955B2/en active Active
- 2016-09-29 HR HRP20161242TT patent/HRP20161242T8/hr unknown
- 2016-10-04 CY CY20161100986T patent/CY1118048T1/el unknown
- 2016-10-05 SM SM201600351T patent/SMT201600351B/it unknown
2017
- 2017-05-12 JP JP2017095523A patent/JP2017145254A/ja not_active Withdrawn
- 2017-11-14 HR HRP20171759TT patent/HRP20171759T8/hr unknown
- 2017-12-06 CY CY20171101286T patent/CY1119684T1/el unknown
2018
- 2018-10-05 HK HK18112717.7A patent/HK1253517B/en unknown
- 2018-12-25 JP JP2018240826A patent/JP2019104732A/ja not_active Withdrawn
2020
- 2020-09-24 JP JP2020159623A patent/JP2021001214A/ja active Pending
- 2020-12-18 NO NO2020046C patent/NO2020046I1/no unknown

Also Published As

Publication number	Publication date
DK2430014T3 (en)	2015-11-30
RS54386B1 (sr)	2016-04-28
EA021974B1 (ru)	2015-10-30
MX360800B (es)	2018-11-16
US20170029408A1 (en)	2017-02-02
RS56654B8 (sr)	2021-06-30
US8669234B2 (en)	2014-03-11
US9981955B2 (en)	2018-05-29
HK1207638A1 (en)	2016-02-05
ME02536B (fr)	2017-02-20
NL300796I2 (fr)	2016-06-30
EA201590073A1 (ru)	2015-06-30
EP2873665B1 (fr)	2016-07-06
CN104230900B (zh)	2018-10-19
ME02321B (me)	2016-06-20
RS56654B1 (sr)	2018-03-30
HUE025983T2 (en)	2016-05-30
SI3002281T1 (sl)	2017-11-30
CN103977406A (zh)	2014-08-13
NZ706236A (en)	2016-07-29
EP3309157A1 (fr)	2018-04-18
RS55249B8 (sr)	2021-06-30
RS55249B1 (sr)	2017-02-28
HUE030465T2 (hu)	2017-05-29
EA026536B1 (ru)	2017-04-28
UY32629A (es)	2010-12-31
TW201504244A (zh)	2015-02-01
NO3002281T3 (fr)	2018-02-10
PT2430014E (pt)	2015-10-20
AP2011005987A0 (en)	2011-12-31
HRP20171759T8 (hr)	2021-05-14
KR101546119B1 (ko)	2015-08-20
TW202042807A (zh)	2020-12-01
AU2010249043B2 (en)	2014-10-09
NO2016004I2 (no)	2016-02-29
IL233678A0 (en)	2014-09-30
PL3002281T3 (pl)	2018-02-28
KR20180028070A (ko)	2018-03-15
MX376550B (es)	2025-03-07
AR076765A1 (es)	2011-07-06
PT3002281T (pt)	2017-11-14
EA037281B1 (ru)	2021-03-04
HRP20171759T1 (hr)	2017-12-29
CY2016001I2 (el)	2018-01-10
UA121454C2 (uk)	2020-06-10
US20140249074A1 (en)	2014-09-04
SG10201402280QA (en)	2014-08-28
CN104211689A (zh)	2014-12-17
PL2873665T3 (pl)	2017-01-31
KR20140014393A (ko)	2014-02-06
KR20160084478A (ko)	2016-07-13
HUS1600001I1 (hu)	2016-02-29
CN106588890A (zh)	2017-04-26
LT2873665T (lt)	2016-10-25
CL2011002825A1 (es)	2012-10-12
TWI465444B (zh)	2014-12-21
WO2010132601A1 (fr)	2010-11-18
US9511056B2 (en)	2016-12-06
NO2020046I1 (no)	2020-12-18
BR122014012810B1 (pt)	2020-04-14
BR122014013631B8 (pt)	2021-05-25
KR101727876B1 (ko)	2017-04-17
ES2596247T3 (es)	2017-01-05
HUE036906T2 (hu)	2018-08-28
JP5744283B2 (ja)	2015-07-08
CY1118048T1 (el)	2018-03-07
EP3626716A1 (fr)	2020-03-25
JP2019104732A (ja)	2019-06-27
BR122014012810A2 (pt)	2017-06-27
US20120264711A1 (en)	2012-10-18
SI2873665T1 (sl)	2017-02-28
AP3622A (en)	2016-03-02
CO6470842A2 (es)	2012-06-29
TWI629981B (zh)	2018-07-21
US20130137877A1 (en)	2013-05-30
IL233679B (en)	2019-05-30
MX2019003738A (es)	2019-07-01
CN104016971A (zh)	2014-09-03
TW201902477A (zh)	2019-01-16
TW201617073A (zh)	2016-05-16
TWI689305B (zh)	2020-04-01
US20140051656A1 (en)	2014-02-20
CY1116942T1 (el)	2017-04-05
NZ596444A (en)	2014-01-31
IL233044A0 (en)	2014-07-31
CN104016971B (zh)	2016-05-25
PT2873665T (pt)	2016-10-13
US8575118B2 (en)	2013-11-05
HRP20151000T1 (hr)	2015-11-20
EP2873665A1 (fr)	2015-05-20
CN104211689B (zh)	2017-01-18
SG176015A1 (en)	2011-12-29
PE20150202A1 (es)	2015-02-13
MX2020011251A (es)	2020-11-12
PE20120509A1 (es)	2012-05-09
JP2021001214A (ja)	2021-01-07
BR122014013631A2 (pt)	2017-06-27
CA2761258A1 (fr)	2010-11-18
CN106588890B (zh)	2020-11-27
SI3309157T1 (sl)	2020-02-28
JP2014148550A (ja)	2014-08-21
ES2758726T3 (es)	2020-05-06
IL233044A (en)	2015-07-30
DK3002281T3 (en)	2017-12-18
MX360803B (es)	2018-11-16
LTPA2016002I1 (lt)	2021-01-11
HRP20151000T8 (hr)	2021-05-14
HK1223365A1 (en)	2017-07-28
NZ619205A (en)	2015-04-24
EA201790515A1 (ru)	2018-10-31
US20120157404A1 (en)	2012-06-21
CN104211713A (zh)	2014-12-17
BR122014013631B1 (pt)	2020-11-17
US20140039021A1 (en)	2014-02-06
CY1119684T1 (el)	2018-04-04
CA2761258C (fr)	2015-08-04
CN103977406B (zh)	2016-10-19
IL233678B (en)	2019-05-30
EP3309157B1 (fr)	2019-09-04
KR20200011049A (ko)	2020-01-31
CN102596936B (zh)	2014-06-11
EA201490854A1 (ru)	2014-09-30
JP5582662B2 (ja)	2014-09-03
FR16C0005I1 (fr)	2016-03-25
ME02916B (fr)	2018-10-20
HK1253517B (en)	2020-04-24
PL2430014T3 (pl)	2016-02-29
RS54386B8 (sr)	2021-06-30
PT3309157T (pt)	2019-12-02
EP3002281A1 (fr)	2016-04-06
IL216254A0 (en)	2012-01-31
PL3309157T3 (pl)	2020-03-31
US8088368B2 (en)	2012-01-03
JP2015157842A (ja)	2015-09-03
EP2857394A1 (fr)	2015-04-08
SMT201500284B (it)	2016-01-08
HK1253517A1 (en)	2019-06-21
LTC2430014I2 (lt)	2021-02-25
IL233042A0 (en)	2014-07-31
IL216254A (en)	2016-08-31
US20100310512A1 (en)	2010-12-09
ECSP11011517A (es)	2012-01-31
EA027493B1 (ru)	2017-07-31
SI2430014T1 (sl)	2015-10-30
EP2430014A1 (fr)	2012-03-21
EP2430014B1 (fr)	2015-08-19
HK1162518A1 (en)	2012-08-31
JP2017145254A (ja)	2017-08-24
IL233679A0 (en)	2014-09-30
JP2014169331A (ja)	2014-09-18
ES2548156T3 (es)	2015-10-14
BRPI1010795B1 (pt)	2018-12-11
CN102596936A (zh)	2012-07-18
EA201490853A1 (ru)	2014-09-30
KR20140122705A (ko)	2014-10-20
CY2016001I1 (el)	2018-01-10
SMT201700570T1 (it)	2018-01-11
CN104230900A (zh)	2014-12-24
CN104211713B (zh)	2017-04-12
EA201190259A1 (ru)	2013-01-30
SMT201600351B (it)	2016-11-10
HRP20161242T1 (hr)	2016-11-18
HRP20161242T8 (hr)	2021-05-14
CN109020961A (zh)	2018-12-18
TWI547495B (zh)	2016-09-01
JP5745727B2 (ja)	2015-07-08
US8841278B2 (en)	2014-09-23
NO2016004I1 (no)	2016-02-17
KR101503752B1 (ko)	2015-03-18
LT3002281T (lt)	2017-12-11
MX363732B (es)	2019-04-01
EP3002281B1 (fr)	2017-09-13
MX2011012058A (es)	2012-04-02
ES2646131T3 (es)	2017-12-12
CA2886322A1 (fr)	2010-11-18
AP2016008993A0 (en)	2016-01-31
TW201632183A (zh)	2016-09-16
TW201105656A (en)	2011-02-16
TW201503888A (zh)	2015-02-01
KR20140122706A (ko)	2014-10-20
US8273341B2 (en)	2012-09-25
DK2873665T3 (en)	2016-11-07
US8822430B2 (en)	2014-09-02
ZA201108436B (en)	2013-01-30
BRPI1010795A2 (pt)	2016-12-20
JP2012526838A (ja)	2012-11-01
AU2010249043A1 (en)	2011-12-01
KR20190029771A (ko)	2019-03-20
KR20170041924A (ko)	2017-04-17

Publication	Publication Date	Title
FR16C0005I2 (fr)	2016-09-30	Composes antiviraux
BRPI1013389A2 (pt)	2016-03-29	fivela
BRPI1008774A2 (pt)	2016-03-08	espiroamida substituída
DK2462134T3 (da)	2014-08-11	N1-sulfonyl-5-fluorpyrimidinonderivater
DK2414015T3 (da)	2021-12-06	Laryngoskopsystem
DK2411442T4 (da)	2021-12-06	Umættet polyesterresin
DE112010004215A5 (de)	2012-08-23	Hydrostataktor
DE112010002949A5 (de)	2012-09-06	Kupplungstastpunkte
EP2406768A4 (fr)	2014-08-20	Structure de délivrance
DK2511282T3 (da)	2014-07-07	Uracylspirooxetannukleosider
BRPI1008827A2 (pt)	2016-02-23	deisobutenizador
DE112010002092A5 (de)	2012-04-26	Fotodetektoren
UA21022S (uk)	2010-10-25	Пряжка
BRPI1014968A2 (pt)	2016-12-13	subalargador
DE112010004249A5 (de)	2012-11-29	Spindelaktor
DE112009005323A5 (de)	2012-07-26	Hebelarmprüfmaschine
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
BR112012004964A2 (pt)	2016-04-05	girocóptero
BRPI1008070A2 (pt)	2016-03-15	tricianoboratos
DK2483126T3 (da)	2015-06-22	Skinnekøretøj
DE112010004865T8 (de)	2013-01-24	Lamellennassreibkupplung
FR2952847B3 (fr)	2011-12-09	>
DK2506968T3 (da)	2020-11-23	Faujasit-zeolit
EP2445917A4 (fr)	2013-01-02	Composes photolabiles
DE112010003255A5 (de)	2013-05-02	Fördergutverteiler